Dilshat Djumanov, Director of Data Science at Richmond Pharmacology explores how GDPR is central to protecting private information. From clinical research to patient monitoring, the collection and sharing of data is key, as outlined by Dilshat Djumanov, Director of Data Science at Richmond Pharmacology. In their PM Live article published today, Djumonov explores how GDPR is central to protecting private information while presenting unique challenges to the pharmaceutical clinical trials industry. The post Brexit control of critical data and the ability to share information adds to the complexity with the UK planning its own reforms under the Data Reform Bill.

These regulatory changes, and other in the various frameworks around the world, are helping the integration of data management tools and realise the potential benefit for both industry and patients of better data-sharing tools. Unlocking the next generation of data sharing, processing and visualisation in clinical trials will be the next great frontier in pharmaceuticals. Medical privacy has been at the core of trial participation for a long time and the clinical research industry is perhaps the most advanced in understanding how to safely handle sensitive personal data.

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

HFA 2025

17–20 May 2025
Richmond Pharmacology will participate in HFA 2025 in Belgrade from 17–20 May, focusing on heart failure research, clinical trials, and scientific collaboration.
View event